Genomic Vision raises €4M for DNA analysis nanotechnology development

Pasteur Institute Paris spin-out, Genomic Vision, has raised €4 million in a Series B financing round led by Vesalius BioCapital and Societe Generale Asset Management Alternative Investments (SGAM AI), to further develop its nanotechnology-based DNA analysis tools for the treatment of cancer and acute diseases.

Genomic Vision uses its proprietary Molecular Combing Technology to visualise DNA molecules and assess gene contributions to disease. Part of the Paris Santé Biotech Network, the company, that holds an exclusive licence from the Pasteur Institute, has previously received €2 million worth of funding from SGAM AI, to further the company’s diagnostic and drug discovery activities in the field of cancer and genetic diseases. Aaron Bensimon, CEO of Genomic Vision, said: “It is particularly rewarding to have SGAM AI renew their confidence in us after investing three years ago.”  

Jean-Yves Nothias, of SGAM AI, said: "Genomic Vision has a unique technology, Molecular Combing, capable of revolutionizing several diagnostic approaches and DNA analysis. We believe very strongly that their genomic tests will be useful for cancers, genetic diseases, viral diseases and many other applications with wide potential markets."

The new funds will improve in-house and collaborative R&D programmes and automation. Bensimon added: “We are pleased to have attracted Vesalius BioCapital, biotechnology entrepreneurial specialists whose skill and experience will be very useful. This support from our investors will help us to develop our products and services more quickly and enable us to take advantage of growing market opportunities."

Stéphane Verdood, of Vesalius BioCapital, said: "We are excited about Genomic Vision's capabilities, which have a significant potential to complete the technical developments required for the use of its molecular combing technology for early cancer diagnosis.”